Butyric Acid

Butyric Acid

SCHEMBL4171971

CCCC(=O)O.COc1cc2[nH]c(=O)c3[nH]ccc3c2cc1S(=O)(=O)N(C)C1CC1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.36
BRD4 O60885 2/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
MCOLN3 Q8TDD5 2/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPT P10636 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
TSHR P16473 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
JAK3 P52333 1/20 0.32
CFB P00751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4171746 0.89 PKM (0.37) PKMBRD4L3MBTL1KEAP1NFE2L2
Butyric Acid SCHEMBL4162510 0.89 PKM (0.37) PKMBRD4MAPTJAK1KDM4E
Butyric Acid SCHEMBL4166911 0.84 RXFP1 (0.43) PKMMEN1KMT2AL3MBTL1MAPT
Butyric Acid SCHEMBL4159473 0.79 RXFP1 (0.40) MEN1KMT2AL3MBTL1MAPTTSHR
SCHEMBL4171968 0.79 PKM (0.35) PKMMCOLN3MEN1HTTKMT2A
Butyric Acid SCHEMBL4157862 0.78 RXFP1 (0.40) MEN1KMT2AL3MBTL1MAPTTSHR
Butyric Acid SCHEMBL4155204 0.78 RXFP1 (0.40) BRD4MEN1KMT2AL3MBTL1MAPT
Butyric Acid SCHEMBL4161012 0.78 ALDH1A1 (0.36) BRD4MEN1KMT2AL3MBTL1MAPT
Butyric Acid SCHEMBL4169377 0.77 KDM4E (0.34) MEN1KMT2AMAPTKEAP1NFE2L2
SCHEMBL3247132 0.76 PKM (0.39) PKMBRD4BRD2BRD3MCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 PKM 276/4885BRD4 545/4885BRD2 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.